AQR Capital Management LLC increased its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 8.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 149,050 shares of the medical instruments supplier’s stock after buying an additional 12,139 shares during the period. AQR Capital Management LLC owned about 0.41% of AngioDynamics worth $2,586,000 as of its most recent filing with the SEC.
Other large investors also recently modified their holdings of the company. BlueCrest Capital Management Ltd acquired a new stake in AngioDynamics during the first quarter valued at approximately $175,000. Highbridge Capital Management LLC acquired a new stake in AngioDynamics during the first quarter valued at approximately $419,000. Bank of America Corp DE raised its stake in AngioDynamics by 580.4% in the first quarter. Bank of America Corp DE now owns 166,555 shares of the medical instruments supplier’s stock valued at $2,890,000 after buying an additional 142,076 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in AngioDynamics by 67.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 234,558 shares of the medical instruments supplier’s stock valued at $4,070,000 after buying an additional 94,282 shares in the last quarter. Finally, Morgan Stanley raised its stake in AngioDynamics by 2.0% in the first quarter. Morgan Stanley now owns 240,773 shares of the medical instruments supplier’s stock valued at $4,176,000 after buying an additional 4,669 shares in the last quarter. Institutional investors own 85.94% of the company’s stock.
AngioDynamics, Inc. (NASDAQ:ANGO) opened at 16.94 on Friday. AngioDynamics, Inc. has a 52 week low of $14.80 and a 52 week high of $18.18. The firm has a market cap of $620.92 million, a P/E ratio of 89.16 and a beta of 1.15. The company has a 50-day moving average of $16.13 and a 200 day moving average of $16.18.
AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Tuesday, July 18th. The medical instruments supplier reported $0.19 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.16 by $0.03. AngioDynamics had a return on equity of 5.19% and a net margin of 2.00%. The business had revenue of $86.90 million during the quarter, compared to analyst estimates of $90.72 million. During the same quarter last year, the company posted $0.19 EPS. AngioDynamics’s revenue for the quarter was down 7.0% on a year-over-year basis. On average, equities analysts predict that AngioDynamics, Inc. will post $0.67 earnings per share for the current year.
Several research firms recently commented on ANGO. BidaskClub lowered shares of AngioDynamics from a “hold” rating to a “sell” rating in a research report on Tuesday. Canaccord Genuity reiterated a “hold” rating and issued a $17.00 price objective on shares of AngioDynamics in a research report on Tuesday, July 18th. Cantor Fitzgerald boosted their price objective on shares of AngioDynamics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 4th. Zacks Investment Research lowered shares of AngioDynamics from a “hold” rating to a “sell” rating in a research report on Thursday, July 20th. Finally, Barclays PLC decreased their price objective on shares of AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 19th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. AngioDynamics currently has an average rating of “Hold” and a consensus target price of $18.50.
In related news, CEO James C. Clemmer purchased 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The stock was acquired at an average price of $15.64 per share, for a total transaction of $312,800.00. Following the transaction, the chief executive officer now directly owns 86,683 shares of the company’s stock, valued at approximately $1,355,722.12. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO James C. Clemmer purchased 5,000 shares of the firm’s stock in a transaction that occurred on Friday, July 21st. The stock was bought at an average price of $15.79 per share, with a total value of $78,950.00. Following the transaction, the chief executive officer now directly owns 86,683 shares in the company, valued at $1,368,724.57. The disclosure for this purchase can be found here. Insiders purchased a total of 25,316 shares of company stock valued at $396,806 in the last quarter. 1.88% of the stock is currently owned by corporate insiders.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
